(AQST) Aquestive Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03843E1047
AQST: Film Formulations, ADHD Treatment, Seizure Medication, Nausea Relief
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a biopharmaceutical company specializing in the development and commercialization of innovative pharmaceutical products. The company focuses on addressing unmet medical needs through its proprietary PharmFilm® technology, which enables the delivery of medications via soluble films. This technology enhances bioavailability, improves patient compliance, and offers a more convenient alternative to traditional oral medications.
The companys commercial portfolio includes Sympazan® (clobazam), an oral soluble film for the treatment of seizures associated with Lennox-Gastaut syndrome; Suboxone®, a sublingual film formulation of buprenorphine and naloxone for opioid dependence; and Zuplenz®, an oral soluble film formulation of ondansetron for chemotherapy-induced nausea and vomiting. Additionally, Aquestive markets Azstarys®, a once-daily treatment for attention deficit hyperactivity disorder (ADHD).
Aquestives pipeline includes Libervant™, a buccal soluble film formulation of diazepam for acute repetitive seizures; KYNMOBI™, a sublingual film formulation of apomorphine for Parkinsons disease; and Exservan™, an oral soluble film formulation of riluzole for amyotrophic lateral sclerosis (ALS). The company is also advancing AQST-108, a sublingual film formulation of systemic epinephrine for non-anaphylaxis conditions, and Anaphylaxis, an epinephrine sublingual film for allergic reactions. Its Adrenaverse™ platform focuses on epinephrine delivery for emergency allergic reactions.
From a technical perspective, AQST is trading at $2.80 with a 20-day moving average of $3.02, indicating recent price weakness. The 50-day and 200-day moving averages are $3.21 and $3.80, respectively, suggesting downside resistance. The average true range (ATR) of 0.19 reflects moderate volatility. On the fundamental side, the company has a market cap of $254.8 million, a price-to-sales ratio of 4.33, and a return on equity (RoE) of 77.48, highlighting strong operational efficiency despite a lack of profitability.
Three-Month Forecast: Based on the technical and fundamental data, AQST is expected to face resistance at the 50-day and 200-day moving averages, potentially capping upside momentum. The stock may oscillate between $2.60 and $3.20 over the next three months, with volatility driven by ATR. Fundamental strength in revenue generation could support the stock, but profitability concerns may limit upside. Investors should monitor pipeline advancements and commercial execution for potential catalysts.
Aquestive Therapeutics is headquartered in Warren, New Jersey, and was incorporated in 2004. For more information, visit https://www.aquestive.com.
Additional Sources for AQST Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AQST Stock Overview
Market Cap in USD | 235m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2018-07-25 |
AQST Stock Ratings
Growth 5y | 8.92% |
Fundamental | 24.3% |
Dividend | 0.0% |
Rel. Strength Industry | -46.4 |
Analysts | 4.56/5 |
Fair Price Momentum | 2.40 USD |
Fair Price DCF | - |
AQST Dividends
No Dividends PaidAQST Growth Ratios
Growth Correlation 3m | -88.3% |
Growth Correlation 12m | -6.2% |
Growth Correlation 5y | -36.5% |
CAGR 5y | 13.00% |
CAGR/Max DD 5y | 0.14 |
Sharpe Ratio 12m | -1.19 |
Alpha | -56.30 |
Beta | 0.95 |
Volatility | 95.78% |
Current Volume | 844.4k |
Average Volume 20d | 1413.1k |
As of March 15, 2025, the stock is trading at USD 2.84 with a total of 844,395 shares traded.
Over the past week, the price has changed by +7.17%, over one month by -14.46%, over three months by -21.11% and over the past year by -45.90%.
Neither. Based on ValueRay Fundamental Analyses, Aquestive Therapeutics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 24.27 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AQST as of March 2025 is 2.40. This means that AQST is currently overvalued and has a potential downside of -15.49%.
Aquestive Therapeutics has received a consensus analysts rating of 4.56. Therefor, it is recommend to buy AQST.
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AQST Aquestive Therapeutics will be worth about 2.7 in March 2026. The stock is currently trading at 2.84. This means that the stock has a potential downside of -4.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.2 | 258.1% |
Analysts Target Price | 10.8 | 281.3% |
ValueRay Target Price | 2.7 | -4.6% |